CX 2020 Partnership Guide

CONTROVERSIES

CHALLENGES

CONSENSUS

CX Partnership Programme Guide 2020

21–24 APRIL 2020 T U E S D AY – F R I D AY OLYMPIA LONDON • UNITED KINGDOM

Aortic Consensus

Peripheral Arterial Consensus

Venous & Lymphatic Consensus

Acute Stroke Consensus

EDUCATION

Vascular Access Consensus

INNOVATION EVIDENCE

CX 2020 Welcome We are pleased to share the CX Partnership Programme Guide 2020 with you. The aim of this Guide is to highlight the main activities of CX 2020 and outline key sponsorship opportunities, including CX Global Stars and Rising Stars, Abstract programme, handson activities at the CX Workshops, space in the Exhibition Hall, live and edited cases, and sponsored symposia.

CX 2020 will conclude another cycle of Controversies, Challenges and Consensus.

Therefore, the programme will focus on Consensus in the core areas of the Symposium: Aortic, Peripheral Arterial, Venous & Lymphatic, Acute Stroke, Vascular Access and iWounds.

The CX approach has always been to promote Education, Innovation, and Evidence and this will continue to be the case in 2020.

CX 2019 saw the successful launch of the new iWounds track, with wound care sessions within the Venous and Peripheral Arterial programmes, a dedicated multidisciplinary iWounds plenary session and the hands-on CX iWounds Workshop. The aim of iWounds is to promote early diagnosis of the underlying conditions of leg/foot tissue loss and encourage interdisciplinary wound management and collaboration – spanning both acute and community services. The ultimate goal is to reduce the number of lower limb amputations.

Another initiative launched in 2019 was the CX Live studio, a dedicating filming area run by our BLearning team – a specialised broadcast group of journalists and production crew. The BLearning team works with industry partners to create bespoke and topical digital education content, mainly videos and panel discussions, that can be distributed in a targeted manner on websites and social media channels (Vascular News, Venous News, Interventional News and the recently launched iWounds News).

Our team looks forward to working with you to deliver the best possible experience for you at CX 2020.

Aortic Consensus

2

Peripheral Arterial Consensus

Venous & Lymphatic Consensus

Acute Stroke Consensus

Vascular Access Consensus

Consensus

Aortic Consensus

Peripheral Arterial Consensus

Venous & Lymphatic Consensus

Abdominal Aortic Consensus Plenary Programme

Peripheral Arterial Consensus Plenary Programme

Venous & Lymphatic Consensus Plenary Programme

Thoracic Aortic Consensus Plenary Programme

CX Peripheral Techniques & Technologies (live and edited cases)

CX Venous Techniques & Technologies (edited cases)

CX Aortic Techniques & Technologies (edited cases)

ilegx

CX Venous Workshop

CX Peripheral Workshop

CX Aortic Workshop

Acute Stroke Consensus

Acute Stroke Consensus Plenary Programme

Vascular Access Consensus

Consensus

Vascular Access Masterclass

iWounds Consensus Plenary Programme

CX Vascular Access Techniques and Technologies (edited cases)

CX iWounds Workshop

CX Vascular Access Workshop

3

Olympia Grand floorplan *Subject to change

Upper Main Auditorium Accessable via Staircase

CX Poster Gallery

Entrance to Lower Main Auditorium

Stairs to Gallery and Upper Main Auditorium

Stairs to Gallery and Upper Main Auditorium

Entrance to Lower Main Auditorium

CX Peripheral Village

Lower Main Auditorium

4

Groun

Stairs to Gallery Suite & Dark Room Learning Centres

m An Introduction to Vascular Surgery

Gallery Suite Learning Centre

CX Aortic Village

CX Vascular Access Village

Speaker Ready Room

Catering

Faculty Lounge

Dark Room Learning Centre

Faculty Registration

Lead Retrieval

Catering

Book & Bag

Registration

Gallery Suite & Dark Room Learning Centres Situated on the Gallery level above the Olympia Room

Entrance

Pillar Hall Learning Centre

London Room Learning Centre

CX Venous City

nd Floor

5

CX 2019 Statistics 4,020 participants attended CX 2019, which took place in Olympia London (London, UK).

Of those who attended, 69% were vascular and endovascular surgeons. But, reflective of CX’s expansive multidisciplinary approach to the management of vascular disease, a substantial number of interventionalists and other cardiovascular specialists were also at the Symposium; both among the Faculty and the audience.

Participation 5000

4000

3000

2000

1000

CX 2019

CX 2018

CX 2017

CX 2016

CX 2015

CX 2014

CX 2013

CX 2012

CX 2011

CX 2010

CX 2009

CX 2008

CX 2007

CX 2006

CX 2005

CX 2004

CX 2003

CX 2002

CX 2001

6

4

3

2

1

0

9

8

7

6

5

4

3

2

1

2000

Speciality

1000

CX 2019

CX 2018

CX 2017

CX 2016

CX 2015

CX 2014

CX 2013

CX 2012

CX 2011

CX 2010

CX 2009

CX 2008

CX 2007

CX 2006

CX 2005

CX 2004

CX 2003

CX 2002

CX 2001

69% Vascular & Endo

10% Interventionalists

9% Vascular scientists

10% Other cardiovasc 2% Other clinicians

69% Vascular & Endovascular surgeons 10% Interventionalists United Kingdom United States Germany Italy Netherlands France Switzerland Brazil China Poland Spain Turkey Greece Portugal Egypt Sweden Belgium Ireland Australia Russia Saudi Arabia Austria Denmark Japan Czech Republic Finland Israel India Singapore Canada Argentina Slovenia South Africa Hungary Mexico Thailand Romania Serbia South Korea New Zealand Norway Slovakia United Arab Emirates Kuwait Taiwan Bulgaria Croatia Lebanon Sri Lanka Ukraine Costa Rica Iraq Jordan Other

9% Vascular scientists and nurses 10% Other cardiovascular specialists 2% Other clinicians

Clinician versus Industry attendance 3000 Clinicians Industry 2500

2000

1500

1000

500

0 2015

2016

2017

2018

2019

Overall attendance was similar to all previous years in the Grand Hall, Olympia. The clinician attendance was higher than last year whilst industry attendance decreased.

0

200

400

600

7

800

CX Pavilion Sponsorship Pavilion sponsors benefit from the highest level of exposure, with a prime position in the exhibition hall.

Hanging cube 10 full registrations 30 company registrations 4 flexi-passes Premium e-blast 6 complimentary tickets to the CX Evening Reception Link from conference website to your homepage Preferential access to a meeting room for hospitality or training 1 leaflet inserted in the delegate bags Workshop participation at no additional cost Gable end Premium educational e-blast 5 flags outside conference venue with sponsor’s logo Gallery rail banner Choice of sponsorship of symposium app or lanyards

8

PLATINUM

GOLD

SILVER

Starting at £200,000

Starting at £125,000

Starting at £75,000

300sqm+ exhibition booth

160sqm+ exhibition booth

80sqm+ exhibition booth

Three 30-minute symposia in Lower or Upper Main Auditorium

Two 30-minute symposia in Lower or Upper Main Auditorium

One 30-minute symposium in Lower or Upper Main Auditorium

CX Daily News package (4 x full page, premium position)

CX Daily News package (4 x full page)

CX Daily News package (4 x half page)

Two CX Daily News e-newsletter adverts

One CX Daily News e-newsletter adverts

              

         

        

CX Major Sponsorship MAJOR SPONSORSHIP 40sqm = £36,000+ (£900 per sqm) 50sqm= £40,000+ (£800per sqm) 40+ sqm exhibition booth Two 30-minute symposia in a Learning Centre 5 full registrations 30 company registrations 2 flexi-passes 6 complimentary tickets to the CX Evening Reception Link from conference website to your homepage Preferential access to a meeting room for hospitality or training 1 leaflet inserted in the delegate bags Workshop participation at no additional cost (includes table top and chairs for the duration of the workshop)

         

9

CX Exhibition Space We offer the option of hiring either exhibition space only or a shell scheme stand as set out below:

Exhibit space only:

Shell scheme stands:

This option is for floor space only. This is not suitable for basic pop up stands but suitable for companies that hire a stand contractor or who have a modular system. This option involves rigorous health and safety checks.

This option is for floor space including white PVC wall panels (2.5m high), ceiling grid, carpet and fascia to open sides with blue infill and name panel in a standard typeface.

Exhibition space Exhibit space only

Shell scheme stands

6 sqm

-

£5,500

9 sqm

-

£8,250

12 sqm

£10,382

£10,753

15 sqm

£12,978

£13,441

18 sqm

£15,573

£16,123

21 sqm

£17,736

-

24 sqm

£20,270

-

Table top

£3,600 (first-time exhibitors only)

For all other sizes not included in the above table, please contact Nathalie Fortin at nathalie@bibamedical.com As an Exhibitor you are entitled to complimentary: 50-word company description listed in the Vascular News Charing Cross Special Edition Workshop participation at no additional cost.

Table top and chairs are provided.

Exhibitor listing on the CX Web-app (www.cx2020app.com) Complimentary company description for NEW exhibitors in the Charing Cross Programme (“Slim Jim”) 50-word product launch description in the Charing Cross Programme (“Slim Jim”) 2x Evening Reception tickets (Thursday 23 April)

10

CX Sponsored sessions Overview In order to support a symposium or learning session, you must be an exhibitor.

Inclusive benefits and services

CX Programme

If you choose to support a symposium or learning session, the following benefits are included:

The CX 2020 programme is already under construction. The aim is to create a skeleton and outline of programme and priorities for 2020 based upon our own feedback and audience feedback from 2019.

Session room rental Faculty registration Statistics on session attendance Technical assistance in the session room CX audience polling system (only available for sessions held in equipped rooms) Promotion in CX marketing material *Sponsors are responsible for all speakers’ expenses (registration, travel and accommodation)

Timeline October–November 2019 31 October: Deadline for submission of symposium or learning session outline (title, objectives, format, chairman and speakers).

Review and input into the sessions by the CX Executive Board.

20 November 2019: Deadline for submission of full symposium or learning session content for final review by the CX Executive Board.

January 2020: Final approval by the CX Executive Board.

Notification of date/time/session/room allocation by the CX Executive Board.

Official invitations sent to chairman and speaker by the CX team on behalf of the CX Executive Board.

February 2020: Management of faculty flights and hotel accommodation.

Information on breakdown of Faculty costs (details of Faculty supported by industry sponsor).

Letters have been written to key opinion leaders, winners of the CX prizes and holders of certificates of merit inviting them to offer topics for the CX Executive Board alongside those offered by key opinion leaders. From September, skeleton programmes of peripheral, abdominal aortic, thoracic aortic, venous, acute stroke, vascular access and iWounds will be outlined. Then it will be time to listen to suggestions from sponsors to see what fits the CX Executive Board outline programme. The Plenary Programme includes live and edited cases, roundtable discussions, and ‘meet the experts’ sessions. Another highlight is the emphasis on hands-on activities in the Exhibition Hall, with the workshops. In addition, sponsored and branded 30-minute Programmes with the option of live and edited cases will be considered.

UEMS CME credits The Charing Cross Symposium is reviewed every year for CME credits by the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). Through an agreement between the UEMS and the American Medical Association (AMA), physicians may convert these credits to an equivalent number of AMA PRA Category 1 Credits in the United States.

UEMS EACCME accreditation is confirmation of the scientific and educational quality of a programme and allows participants to receive CME credits for the time spent on educational activity.

The Charing Cross Symposium 2019 was compliant with the MedTech Europe Code of Ethical Business Practice and we submit our 2019 application in September 2019.

11

LIVE CASE

£30,000 – 30min slot in Upper Main Auditorium £25,000 – 30min slot in Lower Main Auditorium £35,000 – 30min slot Virtual Reality Case

Peripheral or Aortic Techniques & Technologies live case: Sponsors are invited to propose live cases and presentations on specific topics relating to the Main Programme.

SPONSORED LEARNING SESSION

£12,000 – 30 min slot in Learning Centre

Our Learning Centres offer an ideal forum for product launches, ‘meet-the-expert’ sessions and presentations to the audience at CX. Include promotional package: One e-blast to CX delegate list One half page advert in CX Daily News on the day of the session Inclusion of the session in the CX Programme

12

EDITED CASES These edited case sessions are highly interactive, offering significant opportunity for discussion and audience interaction as part of the programme.

The aim of edited cases is to demonstrate a precise technique to an audience using a pre-edited video. The audience is invited to participate and interact during and after the presentation.

CX Aortic and Peripheral Edited Cases - Main Programme

£25,000 + VAT

CX Peripheral Techniques & Technologies (edited cases)

£15,000 + VAT

CX Aortic Techniques & Technologies (edited cases)

£15,000 + VAT

CX Venous Techniques & Technologies (edited cases) In Venous City

CX Vascular Access Techniques & Technologies (edited cases) In Vascular Access Village

CX iWounds Techniques & Technologies

£8,000 – 20min slot in the CX Venous Workshop £5,000 – 20min slot in the CX Vascular Access Workshop £3,000 – 20min slot in the iWounds Village

In iWounds Village

13

CX Hands-on Workshops Hands-on activities will take place in the Exhibition Hall.

As an exhibitor you are offered the opportunity to have a work station at no extra cost, CX provides: Monitor to connect to laptop Trestle table

Physician demonstrator can be suggested.

Company will be responsible for all of their registrations, hotel and travel expenses through an Educational Grant.

2 chairs Electricity Tall cocktail table for monitor Station signage

CX Venous Workshop (Venous City) The CX Venous Workshop is the longest-running and one of the largest of its kind in the world. It covers a wide range of aspects, techniques and procedures.

It forms part of the CX Venous Programme and expands on the technical aspects of key topics from the CX Venous Main Plenary session.

Format In 2020, the workshop will continue offering oneto-one demonstrations by world-leading experts on various superficial and deep venous interventions.

One of the main features of the CX Venous City is provision of open access for delegates to attend

various training stations at their leisure.

The CX Venous Workshop takes place on days 2 and 3 of the Symposium (morning and afternoon).

When: Wednesday - Superficial venous day Thursday - Deep venous day

09.30–10:30 Edited cases 10:30–13:00 Hands-on demonstration 13:00–14:00 Edited cases 14:00–15:30 Hands-on demonstration

CX Peripheral Workshop (Peripheral Village) The CX Peripheral Workshop will be similar in concept to the Venous City which hosts the highly successful CX Venous Workshop.

In the CX Peripheral Workshop world-class experts will cover a wide range of peripheral technologies

and techniques including directional atherectomy, closure devices, stents, guidewires, drug elution for balloons and stents, bioresorbable stents and stent deployment in general.

When: Tuesday - Wednesday 10.00–16:00 Physician demonstration 12:30–13:30 10:00–10:30 15:30–16:00

14

CX Aortic Workshop (Aortic Village) Assembled by Anna Prent, London, UK, and Kevin Mani, Uppsala, Sweden The CX Aortic Workshop sees globally recognised aortic experts speaking and demonstrating crucial

technical skills needed for obtaining best results.

In 2020, the Workshop will focus on imaging for EVAR, TEVAR and complex aortic procedures, from pre-procedural planning, fusion techniques and postprocedure assessment.

When: Tuesday - Wednesday 10.00–16:00 Physician demonstration 12:30–13:30 10:00–10:30 15:30–16:00

CX Vascular Access Workshop (Vascular Access Village) The Vascular Access Skills Workshop provides the necessary hands-on experience in vascular access and the chance to see how experts achieve best results. It demonstrates what techniques and technologies are used, and, importantly, why.

The Workshop forms a part of the CX Vascular Access Course which runs over 3 days: an abstract presentation session (up to 1 day); a vascular access masterclass (1 day) and this practical skills course (1 day).

Format: One-to-one and small group tuition will be provided by leading experts, while around 20 skills stations— including ultrasound assessment, duplex surveillance and various arteriovenous fistula techniques—will be available to help you gain a practical perspective. As it covers the whole spectrum of vascular access, this will be suitable for those new to vascular access as well as those with previous experience.

When: Thursday 10.00–16:00

CX iWounds Workshop (iWounds Village) CX iWounds Workshop aims to create awareness in order to reduce the number of lower limb amputations. iWounds works along three strategic workstreams:

When: Wednesday - 13.30–15:30 Thursday - 09.30–15:30

Interdisciplinary & interprofessional education Early referral Implementation

If you wish to participate, please contact a member of the CX team (page 27).

The deadline for workshop participation is

20 December 2019

15

CX Sponsored Faculty management Chairmen, speakers and trainers involved in sessions supported by industry are considered as CX Faculty. Sponsors have two options regarding the management of their faculty:

Option 1: The industry sponsor undertakes full responsibility for their Faculty transport, registration and accommodation bookings.

Option 2: The CX team will take care of Faculty registration, travel and accommodation bookings on your behalf. For this option there is a 10% administrative fee, charged on travel and accommodation expenses only.

In the event of “shared” speakers, option 2 will apply and the companies involved will be invoiced for their share of speaker expenses.

Faculty reimbursement policy BIBA Medical has a travel and expenses policy which is in line with MedTech Europe guidelines as follows:

Faculty travel allowance:

BIBA Medical policy assumes economy class travel for all Faculty.

The limits are set out below: UK – £200 Europe – €600 US East Coast – US$1,500 Other intercontinental – US$2,000

If the Faculty member needs or wishes to exceed these allowances they must contact the CX team for prior authorisation. Companies may then choose to offer an increased allowance for their intercontinental Faculty (more than 5 hours flight) to enable them to travel business class but this is at the discretion of the company.

Hotel allowance: CX offers Faculty up to three nights’ accommodation at one of the two Faculty hotels.

The Faculty rate for these hotels is c. £200 per night.

Four nights’ accommodation may be provided if the speaker’s assignments deem it necessary, or if travel within three nights is not possible; requests for four nights will be handled on a case by case basis by BIBA Medical.

In line with MedTech Europe guidelines, we will provide a room with single occupancy and will ask Faculty members to cover any additional expenses should they be travelling with a spouse or other guests.

Meals: We provide lunch for delegates within the Exhibition Hall. Faculty members are invited to have lunch in the CX Faculty.

CX Global Stars and Rising Stars For CX 2020 we invite our Pavilion and Major Sponsors to help us identify Stars and Rising Stars who will be selected on merit via an abstract for Faculty status. We invite our Pavilion and Major Sponsors to encourage trained vascular specialists to submit an abstract. From these, the CX Programme Executive Board will select abstracts either for the dedicated CX Stars and Rising Stars auditorium with Peripheral, Venous, Aortic, Acute Stroke, and Vascular Access sessions, or for established

CX programmes if the abstract topic and quality would augment the CX skeleton programmes developed with suggestions already received from key opinion leaders.

Pavilion and Major Sponsors are asked to fund travel and registration costs and CX will cover hotel stay for three nights.

This initiative is in addition to the successful CX Abstract and Poster Presentation sessions.

Submission deadline: 22 September 2019

CX Abstracts and Posters In this category, abstracts are selected by the CX Abstract Board. Outstanding CX abstracts that fit the CX skeleton programmes could lead exceptionally for the abstract to be made available to the CX Programme Executive Board for consideration of promotion to a CX established session with Faculty status in CX 2020 and, if not, in future years. Prizes and certificates of merit for Trainee and Senior presenters will be awarded as in previous years.

Submission deadline: 3 November 2019

16

Networking and meeting rooms Meeting rooms We are able to offer meeting facilities within the Grand Hall to host any size of meeting. The Henley Suite contains meeting rooms which are insulated from the main exhibition space while being directly accessible from the Grand Hall ground floor level via a staircase.

Meeting room

Sizes

Capacity (Boardroom)

Prices per hour

Per day

4 days

Henley Room 1 (per hr)

83.2 sqm

25

POA

POA

£15,000

Henley Room 2 (per hr)

41.1 sqm

16

POA

POA

£10,000

Henley Room 3 (per hr)

21.1 sqm

10

POA

POA

£7,500

Henley Room 4 (per hr)

48.2 sqm

20

POA

POA

£10,000

Purpose built meeting room on gallery level

25 sqm

12-20

£400

£2,000

£6,000

In addition to these rooms, we also offer smaller, private meeting rooms on the gallery level of Grand Hall. These are furnished with a boardroom table and 12 chairs as standard. No AV is included in the cost.

CX Evening Reception CX will host a reception on the evening of Thursday 23 April. An off-site venue is to be confirmed, and tickets will be available for purchase by CX attendees. Pavilion Sponsors receive 8 tickets within their sponsorship packages, Major Sponsors receive 6, and Exhibitors 2.

17

Educational Grants for physicians to attend CX 2020 MedTech Europe rules prohibit member companies from directly sponsoring physicians to attend third-party organised educational events like the CX Symposium, meaning companies cannot directly pay registration, travel or accommodation expenses to individual HCPs to attend CX. Restricted educational grants may be provided to conference sponsors to help off-set costs for participants.

BIBA Medical is the official Conference Sponsor for the Symposium and is an Ethical MedTech Trusted Partner, the certification initiative launched by Ethical MedTech (MedTech Europe’s compliance portal), emphasising our commitment to comply with the industry’s ethical standards.

Our Industry Partners can issue us with an

educational grant and we, the Conference Sponsor, will select recipients based on criteria set by the Industry Partner. Companies will be able to define the type of recipients eligible for the grant but not name individual recipients.

Grants will cover the cost of registration, accommodation during the conference, and travel expenses.

Educational grants must be publicly disclosed, ensuring increased transparency of funds allocated to medical education.

How will the educational grant process work?

We have a per physician package which includes the following:

Full conference registration Access-all-areas pass to the conference at the early-bird rate

£695

3 nights’ accommodation at the grant hotel* Bed & breakfast, single occupancy, at the official CX educational grant hotel (The Copthorne Tara). Requests for 4 nights can be accepted if considered ‘reasonable’ by the selection committee – we ask that you provide guidelines for this should you wish to consider a 4-night package; the additional cost will need to be added to the per person package. Double occupancy/family room upgrades must be paid for by the individual and will therefore not be reported. *This per night rate is subject to availability and is based on receiving a contract within the timescale detailed below

Flight or train travel to and from the conference Please inform us of any company-specific guidelines relating to travel expenses, e.g. out of pocket expenses like taxis or petrol and whether you permit travel outside of conference dates (e.g. for weekend stays before/after the educational activity).

Handling fee This covers travel agency fees and our time spent on the project

TOTAL PER PHYSICIAN - Europe TOTAL PER PHYSICIAN - Middle East TOTAL PER PHYSICIAN - Northeast Asia TOTAL PER PHYSICIAN - Latin America

18

£475*

£500 Europe £700 Middle East £900 Northeast Asia £1500 Latin America £100 £1770 £1970 £2170 £2770

Key milestones: ASAP

Agree heads of terms for the educational grants Sign educational grant contracts, and confirm eligibility criteria Application page to go live

September 2019 9 September 2019

CX registrations are live on this date also

Applicant selection process

September - January

Weekly updates will be provided

Registration of selected applicants The CX Team will manage the registrations giving the physicians one less thing to think about

September - January

Accommodation and travel bookings Working closely with our travel partner, the CX Team will handle all travel and accommodation bookings, adhering to compliance guidelines at all times

Grant application deadline

September - January 22 January 2020

The application deadline is driven by the hotel cut-off date

Deadline for receiving physician’s credit card guarantee Successful candidates will be contacted by the CX Travel Team and will be asked to provide a credit card as a guarantee of their attendance. The card will only be charged in the event of a no-show/late cancellation

Reporting deadline for physicians from France, Belgium, the Netherlands and Turkey Earlier deadline in order to meet national regulations. For reporting in these countries, industry requires unique-to-country data; the CX Team will gather this information during the application process.

Expenses deadline Deadline for the CX Team to obtain expenses from grant recipients (via our travel agency)

Reporting to industry deadline Full reporting of final travel and accommodation costs and refund of unspent grant monies if applicable

Key points to remember about the grant process: We encourage you to publicise the educational grant to your sales teams so they can drive traffic to the application page You are entitled to put a link to the application page on your own company website The application page will be unique to you: it will contain your company logo, will list your specific eligibility criteria and will be accessible only to those directed there via your company website (unless you prefer otherwise) Should it be necessary, the CX Team can advertise the grant on the CX Symposium website and drive additional applications using e-blasts to targeted database lists

31 January 2020

28 February 2020

31 May 2020 31 July 2020

Next steps: 1. Decide how many people you’d like to support to attend CX 2020 2. Confirm the eligibility criteria you’d like us to use when selecting recipients, e.g. vascular surgeons, interventional radiologists, trainees, members of particular institutions, etc.

3. The CX Team can build a dedicated web page for your grant applicants, located on the CX Symposium website 4. Once live, your sales force can direct HCPs to the page via your website For more information please contact cxsymposium@bibamedical.com

19

CX Marketing Outdoor advertising options Banner quantity

Size

Rate per Banner

Pack Rate

A

Lamp post Banners on Hammersmith Road

5

tbc

£1,500

£6,000

B

Flags – outside Olympia Grand Hall

5

2.74m x 1.37m

£1,500

£7,000

A

B

B1

B2

B3

Olympia Grand

B5

Olympia National

Olympia West Olympia Central, Conference Centre, Reception A5

20

B4

A3 A4

A2

A1

Indoor advertising options

Gallery Rail Panels

5m x 2m

£4,500 Cubes A – P

3m x 3m x 3m

£11,500 Foyer Entrance

1.8m x 1.2m

£4,000

Entrance to

30

29

28

2

< Vascular Access Village

1 A

Stairs to Gallery and Upper Main Auditorium

H

Stairs to Gallery and Upper Main Auditorium

L 26

3

C 25

4

5

C

K

B

J

N

23

M

24

D

6

22

7

Aortic Village

E

F

P

Catering

(Aortic Workshop)

D 21

8

Peripheral Village

9

(Peripheral Workshop)

G

Catering

10

17

Book & Bag

11

Pillar Hall Learning Centre

Venous City

(Venous Workshop & Venous Venous Edited City Cases)

12

15

14

13

Speaker Ready Room

E

16

CX Club Lounge

London Room Learning Centre

Registration

Entrance

E3

E2

E4

E5

E6

Lower Main Auditorium

Entrance to Lower Main Auditorium

27

(iWounds Workshop)

Ground Floor

CME

E

Gable End 2

D

£35,000 Gable End

Lower Main Auditorium

Rate per Banner C

E1

Size

Gable End 1

21

On-site advertising options Cost:

Stair risers: There are two double staircases (four staircases in total) from the ground floor to the gallery level within Grand Hall Olympia. The stair risers of each staircase can be branded with a company logo, colour and image which will be seen by all delegates as they access the Main Auditorium.

One double staircase: £12,000 Two double staircases: £20,000 (4 sets of stairs in total)

Each double staircase has the following technical specification: 2 x sub-staircases comprising: 10 steps per flight / 4 flights 40 steps = full set of stairs Each riser: 1500mm wide x 115 mm high – visual size: 1500mm wide x 95mm high

Additional on-site advertising options: Advertising options Delegate bags

Prices POA

Charging stations

Charging stations located in a designated area, with a back wall acknowledging your sponsorship, seating, power and a mention in the final Programme.

£12,000

Room drops

Have your promotional material delivered to delegate rooms at the Symposium hotels.

£3,000

To hotel partners

£6,000

Bag inserts

Delegate bag insert: CX Bag inserts are a shared opportunity and a cost-effective method of promoting your products and/or events.

£2,000

Napkins

Your company logo will appear on 10,000 napkins that will be used during all lunchtimes and tea/coffee breaks over CX.

£4,000

Hotel key cards

22

Descriptions A chance to instantly reach the majority of CX delegates by placing your logo on the CX bag collected on arrival.

per item

Print advertising Our in-house editorial team is responsible for producing four issues of our symposium newspaper, CX Daily News. These newspapers offer opportunities for advertising to our delegates.

Thursday

CX Daily News CX Daily News covers the key stories and events taking place during the symposium. Three of the issues are printed overnight and distributed the following morning.

A total of 4 daily news will be distributed every morning of the Symposium to: Faculty hotels and to all other CX hotels Distributed in exhibition hall

Cost:

Full Page: £8,000 (Includes 4 Full Pages: 1 each day) Half Page: £6,000 (Includes 4 Half Pages: 1 each day)

(#CX2019)

@cxsyposium

Wednesday

sium

/CX sympo

facebook.com

@cxsyposium

(#CX2019)

17 April 2019

Aortic Thoracic es Challeng

ile strategy tened, whis “just ding threa EVAR fun st-effective repair for safe, co corner” around the

sium.com

CX sympo

sium

/CX sympo

facebook.com

18 April 2019

CX App

ews CX Daily N ews CX Daily N deems e nc die au erou While CX not dangw syss, l y Ne t sa xeil clitaa thologis CXpavaD scular pa “truth ta19 ke:s time” sium.com

CX sympo

CX App

See page

15

al Peripher aemia 16 Critical Isch es See page Challeng

unity lar comm UK vascu ht as the and Care Excellence 2019 April EVAR. in the limelig over 15/16 (EVAR) is al Institute for Health us City open repair, UK) released al Veno Aortic sm repair Nation mending omin ngham Abd not in recom ascular aneury ines from thepracti ceApp page 18 ury (Birmi CX dures do sm guidel ility of endov 019)r ascula llengesSee Andrew Bradb that EVAR procea return (#CX2 Chato endov The durab final aortic aneury pread chaired by @cxsyposium mendationsead encouraging 15 awaits the to go sium committee against wides its recom its early stages,ngly See page setsympo ogy was in l guidelines suggested with Service (NHS)—inst increasi (NICE),/CX the technol the clinica which facebook.com lly Health ssr community was In May 2018, ines document the UK National Acce l of a minima the vascula the potentia Vascular ass who a draft guidelal funding from appreciating nt for patients 30 days, justify national aneurysm repair.

Mastercl invasive treatmeopen surgery. At repair open surgic

sium.com

CX sympo

for CX 20 geing establi ensh The Chall nsensus from Building Co rsy Controve

CX 2019

See page

16

nds view iWou over 18 See page

logies ues & Techno Aortic Techniq 8:00 y, 08:00–1

for cular were unfit that endovas over open rity EVAR 1 showed an early superio maintained was resulted in superiority d in longrepair. This years, as observe thereafter for over six up, but results could be term followtrend suggest the followstarted tomay beEVAR. At 10-year

any r inTuesda factorsagainst g Centre n was risk going strable dange ty, came Hall Learnin but, potentially, , this suspicio d—and thus in Pillar majori a demon tly identifie they late catch-up up and beyond there was results, with a 67% analysis on because g op reporting more frequen 8:00 patients Aortic new notion that PTA confirmed, moreEVAR arm. Outlinin Aortic Worksh polling day, 08:00–1 from CX ations modified—in against the nges insightsChalle and Wednes and undergo xel. These y for the n Flooroften mortalit endovascular ed the ramific helmingly presented n explor ting paclita the Workshop, Exhibitio in Tuesday who receive are seen more than thoseissues of this early Session, Fiona voted overw to circula (Hollywood, USA) Sessio and published Aortic the ht ges Delegates body attributed Highlight Challen analysis interventions Ladich Greenhalgh nal Aortic described the CX Highlig the Symposium nos et al meta8:00 el devices. trial at disease] rg, Germany) Experts, Abdomi d by Roger morgan of lar pathologist Elena paclitax arterial (Hambu day, 08:00–1 body. A CX to aneurys the Katsa n was chairen and Thomas Zeller. um Wednes [peripheral Rohlffs rate during ised the behind, due after vascu of paclitaxel in the months on from Main Auditori “This ). The sessio scrutinUpper a very high fell y—mainly w Holde We e mortalit ges ion dies at how EVAR re. all-caus the effects le resolutions four Association (JAHA r Tepe, Andre other stakeholders Challen populat procedu and a from which Aortic hours.

Gunna c after and related we stop ry these ) ers Thoraci of four 8:00five years sac rupture, and possibthe American Heart 08:00–1the how Board memb would die. and UK MHRA the course int, Thursday, Auditorium be focused ondue to seconda Journal of by CX Executive bodies (US FDA ting devices over my standpo patients was should From of everydthree Upper Main dying.two initially there ed much from xel-elu course moderated es of regulatory of followe patients be see that nding paclita should“We EVAR compar medical representativ versy surrou EVAR, but during followthese patients generalfor for their a benefit sure these surgery closely the current contro

in more eight make to open of have to for this trial,n. We nt inferiority ns orin the period after at the close y enrolment conditio treatme having infectio 85% the time of was mortalit dditional polling up—esps.ecially d a novel al Arterial need are not We provide h Proxim revealed that “no patients cause of this this group,” problemThe gesalthoug Peripheral Challen and y committees.

1990s, EVAR in the session t oncology years. patients, differen s believed for its advisor that long-term, these ia y rate with ry rupture Ischaem mortalit

by NICE option for of CX delegate trated in any from seconda 08:00–18:00 , factor on at nd change this stated, ensure Tuesday, to ium ive risk Auditor ht Session Rohlffs. been demons These, he trial data—a ble totopic of discussi y, more aggress CX Highlig ogies said Peripheral Upper Main danger has controlled is attributa much his was the noted. algh, ar—are panel at the body that ion ht Session yesterdan, one al ues & Technol randomised ation,” Ansel A Techniqmodific Thisa convict organ of the signal was the d Roger Greenh ki, data in particul e, withArteri CX Highlig s istic include ci (Londo 8:00 Peripheral 10:00–1 paclitaxel”. when s UK-based mechan (Helsin attendee which the Tara Mastrac Katsano other evidenc Challe of Venermo circulating are nges The lack of Wednesday, Auditorium at “standard consolidated, in which levelled favoured over this implies the data ing (Cambridge, UK) Rohlffs,. Maarit Main hed EVAR as a criticism Defend for Lower was further establis Kim that we main g Lois Spain), who op “Have UK) argued to an NHS reasonin alysis findings in North Americ d, Finland), (Granada, ral Worksh applicable meta-an were asked: substantial levels 08:00–18:00 conclusions, term which et alday, accepte based CX Periphe Wednes g andand David Epstein care”: afor more directly this principle that made are n Floor reducin ology and that is widely sable.

Greece) d new analysis series that there Exhibitio used Tuesday Workshhis a major op, method It was s (Patras, presente r no. trials reimbur 2 in arteriesimplies practice said setting. current Katsano risk a ral togethe d ing ents and/or tinos Periphe circulat increasetrials and 1 and EVAR the clinical respondfunded i, Konstan % ofpublicly s that the the EVARalysis stood in contrast Ischaemia the EVAR o in Helsink closed Critical told argument CX delegate on resource for its significant restenosis”—68 presentation as did the meta-an Peripheral nce by Venerm with the Mastracci’s of aortic guidelines, contributing eltee, with reported in experie ges key issue Ladich, whose on the the effects a paclitax 2 who death of commit ted NICE of Challen of 8:00 page es ion d on spoke with 08:00–1 the session guidelin follow-up then highligh Continue g the applicat opliteal um Thursday, Auditori wall, drawing the session, .

NICE speakers in long-term followin m patients a range of autopsies.nts against the in the femorop ant 15 years of on the artery Lower Main ns. paclitaxel human argume aortic aneurys eluting devices with and signific cular repair set out key the d recommendatio es abdominal consistent ed endovas ion ofpropose ms in from her practice analyses. proporttee’s artery was el- clinical guidelin EVAR 1 comparabdominal aneurys statistical ed that acommit of paclitax At of Forum (VLF; She explain ing howe the across multiple atically 99% certain t coating Explainembolis these open surgery. r Leaders to open repair by to had arrived at Elena Ladich s stated were fit for month’s Vascula gton, DC, USA) drug and excipien the “We are mathem are known to committee not ry outlined patients who ance”, Katsano of Washin ges told “doesBradbu signific Challen eluting devices she says she ions, Additionally, laid out USA). He Lymphaofticthis 1–2 March, to results conclusstresses-making the pathways ated balloons”. & (Columbus, causal links ically, pointing alysis. He discussion 8:00 distally. While drug-co ines forGary Ansel s that a central Venous there are “no y, 08:00–1 emphat meta-an strict decision guidel ial not we dge answer”, Ladich al as ium or Tuesda benefit” the reported tive Main Auditor the looming CX delegate know her knowle tedtonation whether a trial sequent trial is only as good explainand a “protecLower a of asking contes isms ures, ogies potential whether & inal tomechan message “every importance & Technol with “theting devicesor el in the lower point was sium proced Venous neous translum theTechniquesadded, […] The key the of paclitax concerned xel-elu ascularion is Venous (CX) Sympo y”. Ladich lare with plain percuta Thursday ology. should being paclita hatic the end organ”. ic endov associat g patient Crossmortalit could explain day and its method a smoking gun—it Lymp drug intofromcase thorac theofvascu evidenc Charin Wednesel reports see here asty (PTA) and rns regard the limbs paclitax facing shower of stroke nges angioplChalle this lackce—h here is not ave crises findings. You on page 2 seen with Venous City nce, “rarey specialists, d despiteEviden nce, From conce sm repair, s and that mortality ncy of the d Ansel ms, localise In her experie op and and her experie Continue consiste lard surger field in aneurystional tion controisversieclarified ng higher in the meta-analysis. Venous aortic aneury ge of vascu literature vascular isticWorksh y Innova CX on, in eam vasculit both thefrom have describel interna ce, devices the a potential damagi and Thursda ducati was “no mechan d of eviden ated global shorta of severa nsitivity, downstr Wednesday of CX—E neede does not mean g drug-co a timehyperse benefit siumcommented there pillars not exist”.Sympo currently “thisand followinrigour careful review thelitis for such a Venous City comes at This year, CX with a she also sion to organs does l began and pannicu signal to date” scientific However, h discus ed effect the 41sthtannua Session r specialists. the community. treatment”. es from last are no publish The Highlig d and, throug balloon forwar endovascula encapsulate ts. In 2019, and lar of patien the key messag come to way “to date, there specific for vascu es for or summary lead thenotes that outcom findings ence studies and s, order to best possible autopsytional experi with device of el treated reports educa of 28 paclitax in humans made by societie attain the es a unique Challenges meta-analysis us efforts have been the organ toxicity Acute Stroke 7:30 understand thus provid y driving , 13:00–1 Centre trials. Enormo industry to After Monday and g are currentl an that claims. bodies Learnin alysis Acute nt issues r given regulatory Pillar Hall he importa have been d in the meta-an across the vascula Abstracts in the field Stroke Special Session the data presente debates discourse a new CX Acute Stroke high-stakes this session to analyse 16 April, 08:00–11:20 focus, with months of from Challenges Thursday, Learning Centre increased mes. On Tuesday CX Special CX aims in established ges’ community, Dark Room needs to be day of program and clarify what safety perspective, on each full Proximal Arterial ChallenWord to shed problem, ral el: The Last ry and patient forward. the Periphe of an 2 ts Paclitax a regulato suggestion d on page Continue point the way Session highligh discussed 2018 and -eluting attempt to highly el-coated light on the created between paclitax y. Katsanos et al of the association patient mortalit ding the results surroun devices, and uncertainty and uproar

A

T

can I think wethat all agree lifelong we need r nce afte to surveilla it has EVAR—but friendly, entbe pati safe.” simple and

T

Booking deadline is

13 March 2020

Educational Supplements Solidify your educational message with an educational supplement from Vascular News, Venous News or iWounds News Sponsoring a supplement offers a unique opportunity for you to broadcast your company’s core message to your target audience with an educational focus.

The content can be based on the company’s profile, a new product, drug or medical device.

Supplements are inserted in the delegate bags, with additional copies printed for your own use.

Cost: £15,000

Booking deadline is

24 January 2020

23

Targeted Annual Advertising Campaigns Our in house editorial team is responsible for producing Vascular News, Venous News and iWounds News. These newspapers allow your brand the best exposure pre and post show. Each issue is mailed out quarterly to Europe and North America. The websites are updated daily and the top news is sent out via an e-newsletter every 2 weeks.

Vascular News Issue

June

19 82

deems While CX audience erous, paclitaxel not dangist says vascular patholog takes time” h establishing “trut

Kim Hodgson:

Profile

Page 26

Target audience: Vascular Surgeons Topics covered: Aortic, PAD, Vascular Access, Imaging

Page 29

against London, UK) voted to (CX; 15–18 April, of the body attributed Charing Cross Symposium danger in any organ came after vascular Delegates of the was a demonstrable 67% majority, analysis on the the notion that there These polling results, with a insights from new USA) presented circulating paclitaxel.

Session, the FDA Ladich (Hollywood, In a CX Highlight place this June, and pathologist Elena on human tissue and organs. panel set to take explored effects of paclitaxel Data (IPD) review as a range of speakers Individual Patient confirmed their release from industry, on from the Katsanos et al metatransparent data four months (JAHA). Experts, called for more and potential resolutions Heart Association the ramifications in the Journal of the American scrutinised the current wherein drug and other stakeholders analysis published of regulatory bodiesdiscussing the idea of a “trade-off” technology. es representativ ting paclitaxel, for paclitaxel-elu controversy surrounding potential adverse events efficacy may necessitate

EVAR funding threatened, while strategy for safe, cost-effective repair is “just ” around the corner

endovascular aneurysm The durability of the in the limelight as final repair (EVAR) is awaits the UK vascular community the guidelines from aortic aneurysm for Health and Care National Institute set to go against Excellence (NICE), practice in widespread endovascular EVAR. open repair over recommending aortic clinical guidelines In May 2018, the by Andrew Bradbury committee chaired released a draft UK) (Birmingham, which suggested guidelines document,tions that EVAR with its recommenda justify national procedures do not National Health UK funding from the d encouraging a Service (NHS)—instea aneurysm repair. return to open surgical

of the drug and excipient She added that “a proportion distally”, posing the with to embolise

by Roger Greenhalgh coating are known the potential he session was chaired be concerned about Executive Board members and question, “should we moderators and CX Zeller. from her own experience examined Holden and Thomas shower?”. Drawing Gunnar Tepe, Andrew spoke autopsies, Ladich has closed the session, observations with human paclitaxel, Ladich, whose presentation the artery wall, drawing who were treated with on the tissue of patients to organs could on the effects of paclitaxel human any toxicity damage and observations with analysing whether evidence. from her experience but could find no such tissue of patients examining human be found in the body, published reports autopsies, directly stated, “there are no treatments.

“To date,” Ladich organ toxicity in humans who had received paclitaxel are known local and specific of there are of autopsy findings Ladich explained that balloon”, adding there technology, with 4 of paclitaxel-eluting treated with drug-coated Continued on page localised downstream effects describing local aneurysms, “rare case reports” panniculitis. and vasculitis hypersensitivity, downstream

Elena Ladich

T

at a Charing topic of discussion THIS WAS THE London, (CX; 15–18 April, Cross Symposium in which Tara Mastracci UK) Highlight Session, EVAR as “standard of for (London, UK) argued contrast with argument stood in care”. Mastracci’s a range of guidelines, as did the NICE aortic draft who set out key arguments 82 page on page on speakers’ in the session Continued Continued

Annual package including: Five single page adverts Six months online Leaderboard + Half banner A advert* Four e-newsletter banner placements

Cost: £24,000 Venous News Issue

June

19 10

Dominik Heim: The 20th European Venous Forum (EVF)

Page 9

Fedor Lurie:

Profile

Raghu Kolluri: central Role of elevated venous pressure 12 Page

Page 10

VenaSeal maintains y safety and efficac at extended fiveyear follow-up

is required “Urgent action” ral for to improve refer nts venous ulcer patie

of the early intervention Symposium 1 evidence supporting emergence of Level at the Charing Cross being Despite the recent Alun Davies (London, UK) warned tions are consistently improve venous ulceration, UK) that the guidelines and recommenda ulcer patients, to is required for venous (15–18 April, London that “urgent action care”. ignored, and highlighted primary and secondary between referral pathways

data on The first-ever 60-month closure system Medtronic’s VenaSeal at the Charing Cross were presented 15–18 April, London, Symposium (CX; at five years, UK), indicating thatcyanoacrylate treatment with the of diseased adhesive for closurenot inferior to vein segments was arm of the alternative treatment(RFA). Nick ablation radiofrequency Center for Vein the of Morrison USA, delivered the Restoration in Mesa, a superficial venous outcomes during session at CX 2019.

the result of long-term THE DATA WERE a five-year VeClose study, in outcomes from the threeof the trial’s original follow-up extension that, in Morrison explained year follow-up period. efficacy assess the safety and order to continue to system for the long-term to of the VenaSeal closure the investigators “wanted effect of the closure, gather out patients as we could follow up as many patients, original trial’s 222 to five years”. Of the enrol 89 study was able to the extended VeClose to 47 had been randomised to RFA patients, of which and 33 randomised VenaSeal cyanoacrylate system; the remaining with Medtronic’s ClosureFast patients. roll-in cyanoacrylate was nine patients were of the extension study The primary endpoint ultrasound defined as Doppler complete closure, the entirety of first Alun Davies showing closure along Davies presented the trial, examination ulcer segments with reflux ablation) with no discrete major early intervention the treated target vein, lower leg can be a Level 1 evidence supporting 5cm. Among the randomised EVRA trial, he enous ulcers on the ulcers in 2018. The of patency exceeding sustained and social isolation, stimulated ablation for venous of closure rates was source of patient distress impacting the one year on, was partly patients, this endpoint Institute told the CX audience with “no new failures Davies noted, substantially less immediately of the UK National over a long-term period, demonstrated through 60 life. What remains by the lack of translation guidelines into patient’s quality of condition on Excellence (NICE) reported and noninferiority a 91.4% closure rate in that is the burden of this for Health and Care Morrison reported apparent, however, venous ulcers 2013, it was recommendedto of July months”. cost In arm.

RFA estimated practice. the an clinical referred vs. 85.2% in 2 health services. With exceeding leg ulcer should be the VenaSeal arm, Continued on page Health Service (NHS) patients with a venous weeks. However, this to the UK National forecasting of specialist within two Davies pointed to healthcare population a vascular £1 billion each year, went ignored” by 2 given the UK’s ageing recommendation “usually Continued on page this figure to increase, of obesity. venous and growing incidence of the EVRA (Early As principal investigator

V

Target audience: Vascular Surgeons, Venous Specialists, Phlebologists, Interventional Radiologists Topics covered: Endovenous, phlebology

Annual package including: Five single page adverts Six months online Leaderboard + Half banner A advert* Four e-newsletter banner placements

Cost: £20,000 iWounds News June 2019 | Pilot issue

ankleThe benefit of early index brachial pressure vascular measurement for wound care

Keith Harding:

Interdisciplinary wound care Page 5 Page00 Michael Edmonds:

Profile

Wound director of the National (Wakefield, UK), spoke at the member Una AdderleyHealth Service (NHS) England, challenge of the CX Executive Board for the National UK) this year, on argued for Care Strategy Programme (CX; 15–18 April, London, disease. Adderley managing vascular Charing Cross Symposium support that a significant index (ABPI) for claiming the data prevented with its use. ankle-brachial pressure ABPI assessment, disease could be the benefits of introducing due to chronic vascular majority of amputations attending the wound dderley told CX delegates is the “accurate diagnosis care session that an The treatment decision”. foundation of any test for a “relatively accurate” than ABPI is, she argued, more valid and reliable arterial insufficiency—“ more portable than duplex and to literature pedal pulse palpation Adderley pointed scanning”. Furthermore, other diagnostic interpretation with that raises issues of peripheral pulse palpation. tools, methods, such as inaccurate diagnostic In addition to allegedly to an Allthe audience’s attention and Adderly directed vascular on Group report that Party Parliamentary the UK, which highlighted their leg venous disease in loses a patient in England arterial “every two hours, peripheral related to due to complications” opportunity for described this as an disease. Adderley “With early the audience at CX: could be improvement, telling 80% of these amputations arterial assessment, as prevented”. on what she perceived leg Adderly then commented venous for of compression the “suboptimal use published in support from articles ulceration”. Citing of Tissue Viability, Care and Journal Journal of Wound England, that in north-east she informed attendees assessed using foot ulcers are not 23.6% of leg and leg ulcers in and 46% of venous Una Adderley from an Doppler ultrasound, Data compression. not in the same region are evidenced that healthcare district Doppler individual English are not assessed using 33.6% of leg ulcers are not ulcers leg of venous ultrasound, and 25% in the Journal of Wound in compression. Published colleagues at N Srinivasaiah and Care, the study by out to “review Hull (Hull, UK) set of wound the University of practice and the standard current wound-care that wounds England, concluding care” in an area of of morbidity” and cause issue. represent a “significant focus to tackle this recommending a structured wound prevalence for cumulative The study found a

A

Page 8

“Urgent action” is e required to improv referral for venous ulcer patientsevidence

Level 1 Despite recent new intervention supporting the early Alun Davies of venous ulceration, at the Charing (London, UK) warned (15–18 April, Cross Symposium guidelines and the London UK) that are consistently being recommendations that “urgent ignored, and highlighted for venous ulcer action is required referral pathways patients, to improve secondary care”. and between primary

With early arterial of assessment, 80% could these amputations be prevented.”

Continued

on page 2

can be a ON the lower leg VENOUS ULCERS isolation, distress and social major source of patient impacting the Davies noted, substantially remains less life. What of this patient’s quality of however, is the burden cost immediately apparent, services. With an estimated Service condition on health the UK National Health of venous ulcers to Davies £1 billion each year, (NHS) exceeding of this figure to increase, pointed to forecasting population and growing given the UK’s ageing incidence of obesity. of the EVRA (Early As principal investigator trial, Davies ulcer venous reflux ablation) evidence supporting Level 1 presented the first ulcers venous with ablation for early intervention audience trial, he told the CX of in 2018. The EVRA stimulated by the lack one year on, was partly for Health National Institute page 2 translation of the UK Continued on

Target audience: Vascular Surgeons, General Surgeons, Nurses, Podiatrists, Diabetologists, Plastic Surgeons Topics covered: Wound care

Annual package including: Five single page adverts Six months online Leaderboard + Half banner A advert* Four e-newsletter banner placements

Cost: £20,000

24

Digital advertising We offer opportunities for you to increase your presence through the use of digital media. The strong community of physicians who attend CX and read our newspapers can be reached through electronic media.

CX Educational E-blasts Educational E-blasts enable sponsors to share breaking data or symposiums with the entire CX audience within 24hrs The CX team will record your presentation or symposium and send the video to the entire database of 20,000. CX e-blasts receive an average open rate of 30% This opportunity is only available to 8 advertisers Standard rate: £7,500

CX E-blast campaign Whether it’s an invitation to visit your booth or to attend your satellite symposium at Charing Cross, we can email a targeted audience to communicate your message to all delegates.

Rate per e-blast: Standard rate: £2,850 Please contact a member of the CX team (page 27).

CX e-newsletter We are also able to offer advertising opportunities within our CX e-newsletters sent during the CX event highlighting key programme themes and content. The CX e-newsletter is sent to all delegates.

MPU (300 x 250 pxls) x 4 e-newsletters: £2,500 Leaderboard (590 x 72 pxls) x 4 e-newsletters: £2,160

25

CX Live/BLearning The CX Live studio is a dedicated filming area onsite at the CX Symposium.

The studio is manned by a specialised broadcast team of journalists and production crew. We work with industry to create bespoke and topical digital education content, mainly videos and panel discussions, that can be distributed in a targeted manner on our websites and social media channels.

Get in touch with us to plan exciting, social-media friendly, customisable digital education content!

Price n O ption 1 Up to 4 speakers, 3 camera filming, editing and postproduction.

Embedding on Vascular News and Interventional News with e-blast and social media mentions.

Cost: £20,000

n O ption 2 Interview with one physician/ single message, single-camera filming, editing and postproduction.

Embedding on Vascular News with e-newsletter and social media mentions.

Cost: £8,000

n O ption 3 Embedding supplied video on Vascular News or Interventional News website(s). Social media mentions.

Cost: £5,000

n Option 4 Interview with a company representative i.e CEO, CMO. Three questions, one speaker, one 3 min video. The video is yours to use as you like. Limited availability so book your place now.

Cost: £4,000

BLearning - other opportunities

BLearning run roundtables, video interviews and videos inside the operating theatre throughout the year. Feel free to get in touch to discuss how we can work with you and your KOLs across any of the below areas:

n Aortic n Neuro n Spinal n Cardio n Peripheral n Venous n IR n Wounds

26

BIBA MedTech Insights BIBA MedTech Insights is a leading provider of consulting and market analysis serving professionals and organisations in the medical device industry.

We have strong relationships with vascular and endovascular physicians, supported by our connection with the CX Symposium, Vascular News, Venous News and Interventional News.

CX Stand Survey We invite physicians to fill in a general survey at our stand during the conference which we then use to develop our own insights. The survey will cover key controversies being discussed at the Symposium including treatment options available for the superficial femoral artery, management of the short aortic neck, clinical advances in the ascending aorta and the aortic arch and methodologies available for treatment in the superficial and deep venous systems.

For the past 5 years we have averaged around 600 responses. This offers clients a cost-effective alternative to conducting a customised survey. Industry partners are invited to provide questions for inclusion in the floor survey prior to the CX Symposium.

Cost per question from £2,000

Post CX Survey The post CX Survey provides a method of gauging the effectiveness of your marketing activities post CX. With a 5–20 minute bespoke online survey conducted after CX with CX delegates, you can have insight into how effective your strategies are, as well as perceptions of new clinical evidence.

CX Focus Groups/In depth Interviews We are also able to arrange qualitative focus groups which provide an excellent way of gaining input on your products’ characteristics; products either already on the market or yet to be launched. We provide all the necessary equipment and use our CX delegate database to recruit and screen physicians according to your requirements. Projects can range from five to 100 physicians.

Please contact Merveille Anderson at merveille@bibamedical.com

27

Contact the CX team Account Management team: Nathalie Fortin T +44 20 3540 8461

Laura James T +44 20 3540 8472

Shilpa Suthar T +44 20 3540 8471

nathalie@bibamedical.com

laura@bibamedical.com

shilpa@bibamedical.com

For logistical queries please contact a member of the CX Events team: Event Manager

Registration and Hotels

Katie Brunt T +44 20 3540 8468

Petra Holcikova T +44 20 3540 8458

katie@bibamedical.com

petra@bibamedical.com